Nutriband Inc. (NASDAQ:NTRB) Short Interest Update

Nutriband Inc. (NASDAQ:NTRB - Get Free Report) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 281,200 shares, a decrease of 22.1% from the February 13th total of 361,000 shares. Approximately 5.5% of the shares of the stock are sold short. Based on an average daily volume of 204,900 shares, the days-to-cover ratio is presently 1.4 days.

Nutriband Price Performance

Shares of NASDAQ NTRB traded down $0.05 during midday trading on Friday, reaching $6.67. 16,726 shares of the stock traded hands, compared to its average volume of 83,464. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.96 and a quick ratio of 4.83. The stock has a market capitalization of $74.08 million, a PE ratio of -9.39 and a beta of 1.12. Nutriband has a one year low of $2.45 and a one year high of $11.78. The company's 50 day moving average is $6.72 and its 200 day moving average is $5.72.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nutriband stock. Haven Private LLC bought a new stake in shares of Nutriband Inc. (NASDAQ:NTRB - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,561 shares of the company's stock, valued at approximately $54,000. Haven Private LLC owned about 0.10% of Nutriband as of its most recent filing with the Securities and Exchange Commission. 19.70% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Noble Financial started coverage on Nutriband in a research note on Wednesday, January 22nd. They issued an "outperform" rating and a $13.00 price target for the company.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.